MedTrace Logo

BXOS110 Injection in the Treatment of Acute Ischaemic Stroke

NCT06322394 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2024-03-21

No results posted yet for this study

Summary

The purpose of this study was to evaluate the effectiveness of early administration of BXOS110 for injection in reducing overall disability in patients with acute ischaemic stroke.

Conditions

  • Acute Ischemic Stroke

Interventions

DRUG

high-dose BXOS110

3.0 mg/kg, maximum dose not exceeding 300 mg，Participants received one administration by intravenous infusion.

DRUG

low-dose BXOS110

2.0 mg/kg, maximum dose not exceeding 200 mg，Participants received one administration by intravenous infusion.

DRUG

Placebo

Does not contain any test drug active ingredients，Participants received one administration by intravenous infusion.

Sponsors & Collaborators

  • Biocells (Beijing) Biotech Co.,Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-07
Primary Completion
2025-03-31
Completion
2025-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06322394 on ClinicalTrials.gov